<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260428069192N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-28</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the Effect of Blood Injection in the Lower Back Area for Treating Headache After Spinal Anesthesia in Lower Limb Orthopedic Surgery</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of Epidural Blood Patch in Treating Dural Puncture-Related Headache after Lower Limb Orthopedic Surgery: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93522</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in this study will be performed using a pre-generated sequential randomization list. The randomization list will be prepared prior to study initiation by the Principal Investigator using the online randomization platform Randomization.com. This platform utilizes advanced random number generation algorithms to produce unpredictable and unbiased sequences that are fully appropriate for clinical trials. The list will be generated using a random number sequence between ۰ and ۱ with a ۱:۱ allocation ratio. Based on a threshold of ۰.۵, each number will be assigned to one of two groups: D (dexmedetomidine) or P (control). Specifically, if the generated random number is less than ۰.۵, the patient will be allocated to Group D (dexmedetomidine); if the number is ۰.۵ or greater, the patient will be allocated to Group P (control). After the complete list for 72 patients (36 per group) is generated, it will be reviewed and verified by the Principal Investigator to ensure accuracy and the absence of any non-random patterns. The final list will then be stored in a protected file and kept with the Principal Investigator until the start of the study, Blinding description: In this study, due to the nature of the interventions (invasive epidural blood patch vs. conservative medical treatment), blinding of patients and physicians is not feasible. Patients are aware of the treatment received, and physicians perform the procedure. However, the outcome assessor (VAS measurement) and the statistical analyst will be blinded to group allocation. Data will be received using codes A and B, and unblinding will be performed after analysis completion. In case of accidental disclosure of the patient's group, this will be recorded as a "Breach of Blinding" in the data collection form.</study_design>
      <phase>3</phase>
      <hc_freetext>Post-Dural Puncture Headache.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Epidural Blood Patch  will be performed under strict aseptic conditions by an experienced anesthesiologist. Approximately 20 mL of autologous venous blood will be collected from the patient and then slowly injected into the epidural space at or near the previous spinal puncture level. Injection will be stopped immediately if the patient develops significant discomfort, severe back pain, neurological symptoms, or any signs of intolerance during the procedure. Following the intervention, patients will remain under close observation, and vital signs including blood pressure, heart rate, and oxygen saturation will be monitored regularly. Patients will also be evaluated for immediate or delayed procedure-related complications. Intervention 2: Control group: After fascial closure and before skin closure, 100 mg of tramadol hydrochloride dissolved in 20 mL of normal saline will be infiltrated by the surgeon in a layer‑by‑layer, multi‑site manner at the surgical site. The injection technique is identical to Group A: 5 mL injected into the muscle fascia, 10 mL injected into the subcutaneous tissue (in a fan‑shaped manner), and the remaining 5 mL injected into the subdermal layer. Injection will be performed slowly (approximately 2 mL per 10 seconds), and the wound will not be massaged after injection.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is All data will remain confidential in accordance with the ethical commitment, and only aggregated group-level results will be published in the form of a final article or report</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohamad Sorani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 17, Bastani Parizi Alley, Ghods St., Enghelab Ave., Enghelab Sq., Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417744361</zip>
        <telephone>+98 21 8898 3025</telephone>
        <email>msorani@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohamad Sorani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 17, Bastani Parizi Alley, Ghods St., Enghelab Ave., Enghelab Sq., Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417744361</zip>
        <telephone>+98 21 8898 3025</telephone>
        <email>msorani@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing lower limb orthopedic surgery under spinal anesthesia.
Development of post-dural puncture headache (PDPH) according to ICHD-3 criteria.
Age between 18 and 65 years.
ASA physical status class I or II.
Ability to provide written informed consent.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Coagulation disorders or receiving anticoagulant therapy,    Pregnant patients.
Local infection at the puncture site or systemic infection.
History of chronic headache disorders, migraine, or neurological diseases affecting pain perception.
Previous spinal surgery or anatomical abnormalities.
Known allergy to study-related medications.
Severe cardiovascular, hepatic, renal, or systemic disease.
Inability to communicate effectively for reliable pain score assessment.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G97.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other reaction to spinal and lumbar puncture</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Epidural Blood Patch  will be performed under strict aseptic conditions by an experienced anesthesiologist. Approximately 20 mL of autologous venous blood will be collected from the patient and then slowly injected into the epidural space at or near the previous spinal puncture level. Injection will be stopped immediately if the patient develops significant discomfort, severe back pain, neurological symptoms, or any signs of intolerance during the procedure. Following the intervention, patients will remain under close observation, and vital signs including blood pressure, heart rate, and oxygen saturation will be monitored regularly. Patients will also be evaluated for immediate or delayed procedure-related complications.</i_keyword>
      <i_keyword>Control group: After fascial closure and before skin closure, 100 mg of tramadol hydrochloride dissolved in 20 mL of normal saline will be infiltrated by the surgeon in a layer‑by‑layer, multi‑site manner at the surgical site. The injection technique is identical to Group A: 5 mL injected into the muscle fascia, 10 mL injected into the subcutaneous tissue (in a fan‑shaped manner), and the remaining 5 mL injected into the subdermal layer. Injection will be performed slowly (approximately 2 mL per 10 seconds), and the wound will not be massaged after injection.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>"Headache severity" based on VAS at baseline and at 6, 24, 48, and 72 hours post-intervention ( 0 indicates no pain and 10 indicates the worst imaginable pain). Timepoint: Baseline and at 6, 24, 48, and 72 hours post-intervention. Method of measurement: Headache severity will be measured using the Visual Analog Scale (VAS). Time to complete symptom resolution will be recorded based on patient report and clinical assessment. Length of stay will be extracted from the patient's medical records.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>"Need for additional rescue interventions" (repeat epidural blood patch or pharmacological treatment).headache severity more than 6 based on VAS at 6,12,24,72 hours after first intervention. Timepoint: At 6,12, 24, 72 hours post-intervention. Method of measurement: Assessing headache severity after the first intervention at 6, 12, 24, and 72 hours after the first intervention.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-08</approval_date>
        <contact_name>Research Ethics Committees of School of Public Health &amp; Allied Medical Sciences- Tehran University</contact_name>
        <contact_address>No. 17, Bastani Parizi Alley, Ghods St., Enghelab Ave., Enghelab Sq., Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
